Inhibikase grants inducement stock options for 128,000 shares to new hires at $2.055 each
IKT•Inhibikase Therapeutics granted two newly hired non-executive employees options covering 128,000 shares at $2.055 per share, with a 10-year term and staged vesting.
1. Option award details
The options were issued under the company’s 2026 Inducement Equity Plan, effective September 30, 2026. They vest 25% after one year, with the remaining 75% vesting in 36 equal monthly installments.
